 Equillium, Inc. EQ, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that translational data supporting the potential of itolizumab in the treatment of graft-versus-host disease GVHD will be presented at the Transplantation Cellular Therapy TCT Meetings of the American Society for Transplantation and Cellular Therapy ASTCT and the Center for International Blood Marrow Transplant Research CIBMTR being held February 19-23, 2020 at the World Center Marriott in Orlando, Florida. The research, conducted in mouse models of human disease, demonstrates that blockade of the CD6-ALCAM pathway with anti-CD6 antibodies reduces incidence and severity of both GVHD and gastro-intestinal GI inflammation. 